Supplementary Figure S3 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

Bulen, Benjamin J.; Khazanov, Nickolay A.; Hovelson, Daniel H.; Lamb, Laura E.; Matrana, Marc; Burkard, Mark E.; Yang, Eddy Shih-Hsin; Edenfield, William J.; Claire Dees, Elizabeth; Onitilo, Adedayo A.; Buchschacher, Gary L.; Miller, Alan M.; Parsons, Benjamin M.; Wassenaar, Timothy R.; Suga, Jennifer M.; Siegel, Robert D.; Irvin, William; Nair, Suresh; Slim, Jennifer N.; Misleh, Jamal; Khatri, Jamil; Masters, Gregory A.; Thomas, Sachdev; Safa, Malek M.; Anderson, Daniel M.; Mowers, Jonathan; Dusenbery, Anna C.; Drewery, Stephanie; Plouffe, Komal; Reeder, Travis; Vakil, Hana; Patrias, Lynnae; Falzetta, Amanda; Hamilton, Ryan; Kwiatkowski, Kat; Johnson, D. Bryan; Rhodes, Daniel R.; Tomlins, Scott A.

doi:10.1158/2767-9764.23745808.v1

- No file added yet -

Supplementary Figure S3 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

journal contribution

posted on 2023-07-25, 14:20 authored by Benjamin J. Bulen, Nickolay A. Khazanov, Daniel H. Hovelson, Laura E. Lamb, Marc Matrana, Mark E. Burkard, Eddy Shih-Hsin Yang, William J. Edenfield, Elizabeth Claire Dees, Adedayo A. Onitilo, Gary L. Buchschacher, Alan M. Miller, Benjamin M. Parsons, Timothy R. Wassenaar, Jennifer M. Suga, Robert D. Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory A. Masters, Sachdev Thomas, Malek M. Safa, Daniel M. Anderson, Jonathan Mowers, Anna C. Dusenbery, Stephanie Drewery, Komal Plouffe, Travis Reeder, Hana Vakil, Lynnae Patrias, Amanda Falzetta, Ryan Hamilton, Kat Kwiatkowski, D. Bryan Johnson, Daniel R. Rhodes, Scott A. Tomlins

Supplementary Figure S3 shows how Immunotherapy Response Score adds to tumor mutation burden and microsatellite instability status for anti-PD-(L)1 monotherapy clinical benefit

Funding

N/A

History

ARTICLE ABSTRACT

This study confirms the utility of the integrative IRS biomarker for predicting anti-PD-L1/PD-1 benefit. IRS significantly improved upon currently available biomarkers, including PD-L1 IHC, TMB, and MSI status. Additional utility for informing on chemotherapy, anti-PD-L1/PD-1, and anti-PD-L1/PD-1 plus chemotherapy treatments decisions is shown.